enGene Holdings shareholders approve amended 2023 Incentive Equity Plan

enGene Therapeutics Inc.

Shareholders approved amended 2023 Incentive Equity Plan with 25,623,625 votes for and 2,586,367 against at May 15 annual meeting.
Plan amendment changes evergreen provision to annual increase of 5% of outstanding common shares (or smaller as determined by committee).
Directors Paul Hastings (28,201,063 for), Wouter Joustra (28,212,507 for), and Lota Zoth (28,212,007 for) elected.
Appointment of auditor approved with 28,467,217 votes for, no against or abstentions.
Amended plan filed as Exhibit 10.1; effective upon shareholder approval.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

enGene Therapeutics Inc. shareholders approved Approval of Amendment of the enGene Holdings Inc. Incentive Equity Plan at the 2024-05-15 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2024-05-15

Exact text from the filing

Proposal 2 – Approval of Amendment of the enGene Holdings Inc. Incentive Equity Plan For Against Abstain Broker Non-Votes 25,623,625 2,586,367 2,515 254,710

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

enGene Therapeutics Inc. shareholders approved Election of Directors at the 2024-05-15 meeting.

Proposal: director election
Outcome: passed
Meeting: 2024-05-15

Exact text from the filing

Proposal 1 – Election of Directors Director Nominee For Withhold Broker Non-Votes Paul Hastings 28,201,063 11,444 254,710 Wouter Joustra 28,212,507 - 254,710 Lota Zoth 28,212,007 500 254,710

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

enGene Therapeutics Inc. shareholders approved Appointment and Remuneration of Auditor at the 2024-05-15 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2024-05-15

Exact text from the filing

Proposal 3 – Appointment and Renumeration of Auditor For Withhold Broker Non-Votes 28,467,217 - -

View on SEC.gov

637 shareholder votes filed in the last 30 days. Browse all shareholder votes →

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-060449

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.